Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK2455 + Avelumab in Urothelial Carcinoma
NCT03915405Phase 1Terminated
- Sponsor
- Kyowa Kirin
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HTX-201 in urothelial carcinoma (UC), sponsored by Kyowa Kirin. Primary endpoint: Number of participants with treatment-related adverse events up to 24 months. Started Sep 2019; status: terminated.
02
Drugs
HTX-201
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03915405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915405.